Last €87.13 EUR
Change Today +0.86 / 0.99%
Volume 0.0
BUWA On Other Exchanges
New York
New York
As of 2:20 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

bio-rad laboratories-a (BUWA) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/21/14 - €96.80
52 Week Low
09/25/13 - €84.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIO-RAD LABORATORIES-A (BUWA)

Related News

No related news articles were found.

bio-rad laboratories-a (BUWA) Related Businessweek News

No Related Businessweek News Found

bio-rad laboratories-a (BUWA) Details

Bio-Rad Laboratories, Inc. manufactures and supplies products and systems used to separate complex chemical and biological materials, as well as to identify, analyze, and purify their components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls that serve clinical laboratories in the diagnostics market. Its products address specific niches within the in vitro diagnostics (IVD) test market. This segment sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force and a service network worldwide. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

7,750 Employees
Last Reported Date: 03/18/14
Founded in 1952

bio-rad laboratories-a (BUWA) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $810.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $423.3K
Executive Vice President and President of The...
Total Annual Compensation: $577.0K
Executive Vice President and President of The...
Total Annual Compensation: $498.4K
Executive Vice President of International Sal...
Total Annual Compensation: $406.7K
Compensation as of Fiscal Year 2013.

bio-rad laboratories-a (BUWA) Key Developments

Bio-Rad Launches New Human Metabolic and Hormone Immunoassays

Bio-Rad Laboratories, Inc. has launched its new Bio-Plex Pro RBM human metabolic and hormone assays. Developed in partnership with Myriad RBM, Inc., these multiplex immunoassays permit robust and simultaneous quantification of a highly relevant set of protein biomarkers for the study of diabetes, obesity, and metabolic syndrome, as well as related conditions such as cardiovascular disease and inflammation. To better understand the relationship between metabolic and cardiovascular conditions, researchers need to study a wide range of disease-associated biomarkers, including gut and pituitary hormones, acute phase proteins, adipokines, nutrient-binding proteins, and growth factors. Because these biomarkers often act in concert, researchers would benefit greatly from the ability to simultaneously measure multiple analytes in a single blood or cell culture sample. The new Bio-Plex Pro RBM Human Metabolic and Hormone Assays were designed to meet this need. Bio-Plex Pro RBM Human Metabolic and Hormone Assays comprise seven distinct multiplex panels for the detection of 39 analytes, of which 15 are unique to Bio-Rad's panels. Myriad RBM's collaboration with Sanofi and the Population Health Research Institute (PHRI) in testing samples from the ORIGIN diabetes clinical trial was instrumental in the selection of markers in these panels. Bio-Plex Pro RBM Assays are validated to meet rigorous analytical standards and manufactured in accordance with GMP guidelines which provide reproducible data with a correlation specification of R2 = 0.9 based on sample testing in just 3.5 hours through the use of magnetic beads and the fastest assay protocols. Bio-Plex Pro RBM Human Metabolic and Hormone Assays are compatible with the Bio-Plex 100/200, Bio-Plex 3D, and Bio-Plex MAGPIX Platforms, as well as all other Luminex-based xMAP Instruments and Software.

Bio-Rad Laboratories Launches New Reagent for qPCR Analysis

Bio-Rad Laboratories, Inc. has launched SsoAdvanced Universal Inhibitor-Tolerant SYBR Green Supermix, a solution for obtaining reproducible, optimal-quality qPCR data from challenging samples. Generating quality qPCR data from difficult-to-amplify samples such as crude lysates from plants, tissues, formalin-fixed paraffin-embedded samples, and other less-than-ideal sources that contain PCR inhibitors can be challenging and frustrating. In these situations, PCR may be greatly inhibited, making it nearly impossible for researchers to obtain reliable data, wasting time and money. SsoAdvanced Universal Inhibitor-Tolerant SYBR Green Supermix provides all of the advantages of other Bio-Rad supermixes with the added benefit of inhibitor tolerance. The formulation of the SsoAdvanced Universal Inhibitor-Tolerant SYBR Green Supermix has been optimized and validated to tolerate a wider spectrum of PCR inhibitors than competing SYBR Green reagents. These inhibitors include those found in crude lysates, polysaccharides and polyphenols, and various reagents left over from sample prep such as ethanol, isopropanol, EDTA, and sodium chloride. As with all SsoAdvanced Supermixes, the inhibitor-tolerant version includes Bio-Rad's Sso7d-fusion polymerase, which is engineered for enhanced qPCR performance. The supermix is compatible with all real-time PCR instruments and functions under any reaction condition.

QC Laboratories Selects Bio-Rad Laboratories, Inc.'s Foodborne Pathogen Detecting Solution

Bio-Rad Laboratories, Inc. has announced that QC Laboratories has selected Bio-Rad's iQ-Check Prep Automation Solution for detecting foodborne pathogens. QC Laboratories, Lean Six Sigma process analysis revealed that Bio-Rad's pathogen detection method outperformed the methods the laboratory previously used in accuracy, time efficiency, and cost effectiveness. The iQ-Check Prep Automation Solution consists of the iQ-Check Prep System, a liquid handling system that automates sample preparation for real-time PCR, and iQ-Check Real-Time PCR Kits. In addition, she values that the iQ-Check Prep System can detect whether a sample is present, which prevents misinterpretation of a negative result.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BUWA:GR €87.13 EUR +0.86

BUWA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $39.24 USD +0.65
BioMerieux €78.08 EUR +0.91
DiaSorin SpA €30.50 EUR -0.14
PerkinElmer Inc $47.65 USD 0.00
Siemens Ltd 900.10 INR -7.30
View Industry Companies

Industry Analysis


Industry Average

Valuation BUWA Industry Range
Price/Earnings 53.4x
Price/Sales 1.6x
Price/Book 1.5x
Price/Cash Flow 43.7x
TEV/Sales 0.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIO-RAD LABORATORIES-A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at